

# Eric L Haseltine

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3914817/publications.pdf>

Version: 2024-02-01

5  
papers

103  
citations

1937685

4  
h-index

2272923

4  
g-index

5  
all docs

5  
docs citations

5  
times ranked

147  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 708-713.	0.7	44
2	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 68-77.	0.7	37
3	Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor. <i>Pulmonary Therapy</i> , 2020, 6, 275-286.	2.2	15
4	Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment. <i>PLoS Computational Biology</i> , 2014, 10, e1003772.	3.2	7
5	Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 681-698.	1.8	0